These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 32706907)

  • 1. Choosing the optimal HPV vaccine: The health impact and economic value of the nonavalent and bivalent HPV vaccines in 48 Gavi-eligible countries.
    Burger EA; Portnoy A; Campos NG; Sy S; Regan C; Kim JJ
    Int J Cancer; 2021 Feb; 148(4):932-940. PubMed ID: 32706907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.
    Goldie SJ; O'Shea M; Campos NG; Diaz M; Sweet S; Kim SY
    Vaccine; 2008 Jul; 26(32):4080-93. PubMed ID: 18550229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Clinical and Economic Impact of a Nonavalent Versus Bivalent Human Papillomavirus National Vaccination Program in Taiwan.
    Chou HH; Chang SC; Sukarom I; Saxena K; Pavelyev A; Wu YH; Chang CJ
    Value Health Reg Issues; 2022 Nov; 32():79-87. PubMed ID: 36116338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of the nonavalent human papillomavirus vaccine for the prevention of cervical cancer in Singapore.
    Phua LC; Choi HCW; Wu J; Jit M; Low J; Ng K; Pearce F; Hall C; Abdul Aziz MI
    Vaccine; 2021 Apr; 39(16):2255-2263. PubMed ID: 33744050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India.
    Diaz M; Kim JJ; Albero G; de Sanjosé S; Clifford G; Bosch FX; Goldie SJ
    Br J Cancer; 2008 Jul; 99(2):230-8. PubMed ID: 18612311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.
    Gomez JA; Lepetic A; Demarteau N
    BMC Public Health; 2014 Nov; 14():1222. PubMed ID: 25424716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Public health impact and cost-effectiveness of switching from bivalent to nonavalent vaccine for human papillomavirus in Norway: incorporating the full health impact of all HPV-related diseases.
    Diakite I; Nguyen S; Sabale U; Pavelyev A; Saxena K; Tajik AA; Wang W; Palmer C
    J Med Econ; 2023; 26(1):1085-1098. PubMed ID: 37608730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study.
    Jit M; Brisson M; Portnoy A; Hutubessy R
    Lancet Glob Health; 2014 Jul; 2(7):e406-14. PubMed ID: 25103394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health and economic benefits of single-dose HPV vaccination in a Gavi-eligible country.
    Burger EA; Campos NG; Sy S; Regan C; Kim JJ
    Vaccine; 2018 Aug; 36(32 Pt A):4823-4829. PubMed ID: 29807710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-consequences evaluation between bivalent and quadrivalent HPV vaccines in Italy: the potential impact of different cross-protection profiles.
    Capri S; Gasparini R; Panatto D; Demarteau N
    Gynecol Oncol; 2011 Jun; 121(3):514-21. PubMed ID: 21334734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact and Cost-Effectiveness of Human Papillomavirus Vaccination Campaigns.
    Portnoy A; Campos NG; Sy S; Burger EA; Cohen J; Regan C; Kim JJ
    Cancer Epidemiol Biomarkers Prev; 2020 Jan; 29(1):22-30. PubMed ID: 31666282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and economic impact of school-based nonavalent human papillomavirus vaccine on women in Singapore: a transmission dynamic mathematical model analysis.
    Tay SK; Hsu TY; Pavelyev A; Walia A; Kulkarni AS
    BJOG; 2018 Mar; 125(4):478-486. PubMed ID: 29266694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Burden of disease associated with cervical cancer in malaysia and potential costs and consequences of HPV vaccination.
    Aljunid S; Zafar A; Saperi S; Amrizal M
    Asian Pac J Cancer Prev; 2010; 11(6):1551-9. PubMed ID: 21338196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
    Demarteau N; Van Kriekinge G; Simon P
    Vaccine; 2013 Aug; 31(37):3962-71. PubMed ID: 23777952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.
    Võrno T; Lutsar K; Uusküla A; Padrik L; Raud T; Reile R; Nahkur O; Kiivet RA
    Vaccine; 2017 Nov; 35(46):6329-6335. PubMed ID: 28899625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cervical cancer prevention in Indonesia: An updated clinical impact, cost-effectiveness and budget impact analysis.
    Setiawan D; Andrijono ; Hadinegoro SR; Meyta H; Sitohang RV; Tandy G; Perwitasari DA; Postma MJ
    PLoS One; 2020; 15(3):e0230359. PubMed ID: 32203527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis.
    Van de Velde N; Boily MC; Drolet M; Franco EL; Mayrand MH; Kliewer EV; Coutlée F; Laprise JF; Malagón T; Brisson M
    J Natl Cancer Inst; 2012 Nov; 104(22):1712-23. PubMed ID: 23104323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada.
    Kohli M; Lawrence D; Haig J; Anonychuk A; Demarteau N
    BMC Public Health; 2012 Oct; 12():872. PubMed ID: 23061913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential cost-effectiveness of the nonavalent human papillomavirus (HPV) vaccine.
    Drolet M; Laprise JF; Boily MC; Franco EL; Brisson M
    Int J Cancer; 2014 May; 134(9):2264-8. PubMed ID: 24174175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Present status of human papillomavirus vaccine development and implementation.
    Herrero R; González P; Markowitz LE
    Lancet Oncol; 2015 May; 16(5):e206-16. PubMed ID: 25943065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.